How to make the internationalization path of Chinese pharmaceutical enterprises wider and wider?

[market analysis of pharmaceutical Station] in recent years, the export of pharmaceutical preparations has become one of the important signs for Chinese pharmaceutical enterprises to go global Data shows that in 2018, China's pharmaceutical exports to developed markets reached US $2.372 billion, up 38.39% year on year Among them, the export growth of standardized markets to Europe, the United States and Japan was significant and steady, and the internationalization process of preparations continued to accelerate According to the industry, at present, the competition in the pharmaceutical industry is increasing and the industry concentration is increasing Many pharmaceutical enterprises focus on the future development of the industry and gradually carry out pharmaceutical internationalization projects For example, in terms of international market strategy, Hengrui pharmaceutical, the "first brother of pharmaceutical research and development", focuses its attention on injection and other fields with complex technology and high technical difficulty, as well as anti-tumor, surgical anesthesia and other fields with large market capacity With the continuous development of the pharmaceutical industry, many pharmaceutical enterprises, taking advantage of the company's API and pharmaceutical technology, carry out international construction projects, and will complete the registration applications of FDA and nmpa in the United States and China simultaneously, so as to realize the simultaneous listing and sales of products in the Chinese and American markets In addition, pharmaceutical companies will accelerate the pace of transformation, upgrading and international development, adhere to innovation driven development, and leap from generic generic drugs to new dosage forms of drugs, innovative drugs, biological drugs and other fields One belt, one road to internationalization, is also needed to achieve global layout According to the 13th five year plan for the development of pharmaceutical industry, we should implement the strategic development goal of pharmaceutical internationalization, comprehensively improve the export scale, proportion and added value of Chinese pharmaceutical products, and focus on expanding the markets of developed countries and emerging pharmaceutical markets To a great extent, the policy support has also promoted the internationalization process of Chinese pharmaceutical enterprises According to the data, in 2017, Chinese pharmaceutical companies have made great achievements in the internationalization of pharmaceutical preparations, with a total of 38 anda approval numbers for local enterprises, setting a new record Pharmaceutical companies are full of momentum However, the internationalization of Chinese pharmaceutical enterprises is still in its infancy, but the overall level is still weak The industry pointed out that the pharmaceutical industry is facing challenges such as weak overall competitiveness, weak international thinking and concept, overcapacity and low-level repeated construction leading to excessive competition of homogeneity, serious imbalance of input and output, and the profitability of China's drug export still needs to be improved Specifically, on the one hand, in the process of internationalization of Chinese pharmaceutical enterprises, there are big obstacles due to conflicts with foreign cultures and consciousness In recent years, although the reform of the pharmaceutical regulatory system has been accelerated, the long-term conservative regulatory model has not yet brought the product approval, standard management, inspection and testing into line with international standards Therefore, pharmaceutical enterprises need to strengthen the internationalization rules, understand the requirements of pharmaceutical internationalization on product registration, quality, production and other aspects, find out their own positioning and focus, and make the standards of all aspects of products consistent with international standards On the other hand, China's pharmaceutical enterprises need to pay more attention to product quality improvement and process innovation, and work hard to meet the increasingly stringent regulatory requirements at home and abroad At present, some pharmaceutical enterprises cooperate with foreign pharmaceutical enterprises to reduce the risk in the international production process of pharmaceutical products, so as to improve the quality of products In general, in the context of global competition, the internationalization of Chinese pharmaceutical enterprises needs to consider the relationship and interests of both sides, keep learning to follow the international standard rules, and constantly improve the quality and technology level of their own pharmaceutical products, so as to make the internationalization path of enterprises wider and wider.